Gossamer Bio Inc (GOSS) - News Archive

In the evolving landscape of biotechnology, few players exhibit the potential and strategic foresight seen in Gossamer Bio, Inc. (Nasdaq: GOSS). As a clinical-stage biopharmaceutical entity committed to addressing the u...

Gossamer Bio s Strategic Moves in the Face of Market Expectations San Diego-based Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, has recently made significant strides in its journey focus...

In a move set to bolster its workforce and strengthen its ongoing research efforts, Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, recently announced the Compensation Committee of its Boa...

Gossamer Bio Grants Stock Options to Non-Executive EmployeeSan Diego-based biopharmaceutical company, Gossamer Bio, has recently announced that its Compensation Committee has approved a stock option grant to a new non-e...

Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are severe and potentially life-threatening conditions affecting the pulmonary vasculature. As current...

Gossamer Bio Announces Positive First Quarter 2024 Financial Results and Advances in Development of Seralutinib for Pulmonary Hypertension TreatmentSAN DIEGO - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biophar...

Pulmonary hypertension is a life-threatening condition characterized by high blood pressure in the arteries of the lungs, causing difficulty breathing and limited physical activity. With this collaboration, Gossamer and...

Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are debilitating conditions characterized by elevated blood pressure in the pulmonary arteries, leading...

CSIMarket.com is delighted to highlight the latest milestone from the biopharmaceutical universe. In recent news from the clinical-stage biopharmaceutical company, Gossamer Bio, Inc., one can witness a significant strid...